PT1590351E - Processos para a produção de alcalóides de quinazolina - Google Patents
Processos para a produção de alcalóides de quinazolina Download PDFInfo
- Publication number
- PT1590351E PT1590351E PT04704202T PT04704202T PT1590351E PT 1590351 E PT1590351 E PT 1590351E PT 04704202 T PT04704202 T PT 04704202T PT 04704202 T PT04704202 T PT 04704202T PT 1590351 E PT1590351 E PT 1590351E
- Authority
- PT
- Portugal
- Prior art keywords
- compound
- iii
- process according
- salt
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 59
- 229930002339 quinazoline alkaloid Natural products 0.000 title description 5
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 58
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000002425 crystallisation Methods 0.000 claims description 22
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 22
- 230000008025 crystallization Effects 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 15
- 238000006722 reduction reaction Methods 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 239000012362 glacial acetic acid Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- VARHXCYGZKSOOO-UHFFFAOYSA-N Deoxyvasicinone Chemical compound C1=CC=C2C(=O)N(CCC3)C3=NC2=C1 VARHXCYGZKSOOO-UHFFFAOYSA-N 0.000 description 44
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- YIICVSCAKJMMDJ-JTQLQIEISA-N (3s)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol Chemical compound C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003246 quinazolines Chemical class 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KTCXMTWSISEJFZ-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-pyrrolo[2,1-b]quinazolin-10-ium;chloride Chemical compound Cl.C1C2=CC=CC=C2N=C2N1CCC2 KTCXMTWSISEJFZ-UHFFFAOYSA-N 0.000 description 2
- 240000005523 Peganum harmala Species 0.000 description 2
- 235000005126 Peganum harmala Nutrition 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 3H-quinazolinyl-4-one Natural products C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- SYLRFDTUTMLVNM-UHFFFAOYSA-N 4-phenoxybutanoyl chloride Chemical compound ClC(=O)CCCOC1=CC=CC=C1 SYLRFDTUTMLVNM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000006214 Clemmensen reduction reaction Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910003556 H2 SO4 Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304141A DE10304141B4 (de) | 2003-02-03 | 2003-02-03 | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1590351E true PT1590351E (pt) | 2008-11-21 |
Family
ID=32747532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04704202T PT1590351E (pt) | 2003-02-03 | 2004-01-22 | Processos para a produção de alcalóides de quinazolina |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7495096B2 (https=) |
| EP (1) | EP1590351B1 (https=) |
| JP (1) | JP2006516578A (https=) |
| KR (1) | KR20050096165A (https=) |
| CN (1) | CN100558727C (https=) |
| AR (1) | AR042946A1 (https=) |
| AT (1) | ATE407135T1 (https=) |
| AU (1) | AU2004208873B2 (https=) |
| BR (1) | BRPI0407012A (https=) |
| CA (1) | CA2514945A1 (https=) |
| DE (2) | DE10304141B4 (https=) |
| DK (1) | DK1590351T3 (https=) |
| EA (1) | EA009047B1 (https=) |
| ES (1) | ES2314366T3 (https=) |
| MX (1) | MXPA05008179A (https=) |
| MY (1) | MY141734A (https=) |
| NO (1) | NO20053689L (https=) |
| NZ (1) | NZ541101A (https=) |
| PL (1) | PL378406A1 (https=) |
| PT (1) | PT1590351E (https=) |
| SI (1) | SI1590351T1 (https=) |
| TW (1) | TW200418811A (https=) |
| UA (1) | UA81287C2 (https=) |
| WO (1) | WO2004069836A1 (https=) |
| ZA (1) | ZA200505160B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004048927A1 (de) * | 2004-10-06 | 2006-04-20 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren |
| EP3661502A4 (en) | 2017-08-03 | 2020-12-02 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES |
| KR102728780B1 (ko) * | 2021-11-30 | 2024-11-08 | 이화여자대학교 산학협력단 | 데옥시바시시논을 유효성분으로 포함하는 미백용 조성물 및 상기 데옥시바시시논 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU605614A1 (ru) * | 1971-10-20 | 1978-05-05 | Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср | Антихолинэстеразное средство |
| JP3180464B2 (ja) * | 1991-08-30 | 2001-06-25 | 新日本理化株式会社 | ジアセタール化合物の製造方法 |
| DE19530606A1 (de) * | 1995-08-21 | 1997-02-27 | Basf Ag | 1-(Pyridyl)-pyrazole |
| JP3958452B2 (ja) * | 1997-10-31 | 2007-08-15 | 大日精化工業株式会社 | 新規化学発光試薬及びその製造方法 |
| DE19906975B4 (de) | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
| DE19906979B4 (de) | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DE19906978B4 (de) | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
-
2003
- 2003-02-03 DE DE10304141A patent/DE10304141B4/de not_active Expired - Fee Related
-
2004
- 2004-01-22 DK DK04704202T patent/DK1590351T3/da active
- 2004-01-22 DE DE502004007980T patent/DE502004007980D1/de not_active Expired - Lifetime
- 2004-01-22 EA EA200501135A patent/EA009047B1/ru not_active IP Right Cessation
- 2004-01-22 AT AT04704202T patent/ATE407135T1/de active
- 2004-01-22 KR KR1020057013954A patent/KR20050096165A/ko not_active Ceased
- 2004-01-22 AU AU2004208873A patent/AU2004208873B2/en not_active Ceased
- 2004-01-22 WO PCT/EP2004/000485 patent/WO2004069836A1/de not_active Ceased
- 2004-01-22 US US10/544,265 patent/US7495096B2/en not_active Expired - Fee Related
- 2004-01-22 CN CNB2004800034182A patent/CN100558727C/zh not_active Expired - Fee Related
- 2004-01-22 ES ES04704202T patent/ES2314366T3/es not_active Expired - Lifetime
- 2004-01-22 NZ NZ541101A patent/NZ541101A/en not_active IP Right Cessation
- 2004-01-22 PL PL378406A patent/PL378406A1/pl not_active Application Discontinuation
- 2004-01-22 BR BR0407012-7A patent/BRPI0407012A/pt not_active Application Discontinuation
- 2004-01-22 JP JP2006501573A patent/JP2006516578A/ja active Pending
- 2004-01-22 EP EP04704202A patent/EP1590351B1/de not_active Expired - Lifetime
- 2004-01-22 CA CA002514945A patent/CA2514945A1/en not_active Abandoned
- 2004-01-22 MX MXPA05008179A patent/MXPA05008179A/es active IP Right Grant
- 2004-01-22 SI SI200430943T patent/SI1590351T1/sl unknown
- 2004-01-22 UA UAA200507716A patent/UA81287C2/uk unknown
- 2004-01-22 PT PT04704202T patent/PT1590351E/pt unknown
- 2004-01-28 AR ARP040100246A patent/AR042946A1/es unknown
- 2004-01-30 MY MYPI20040294A patent/MY141734A/en unknown
- 2004-02-02 TW TW093102290A patent/TW200418811A/zh unknown
-
2005
- 2005-06-24 ZA ZA200505160A patent/ZA200505160B/en unknown
- 2005-07-29 NO NO20053689A patent/NO20053689L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL378406A1 (pl) | 2006-04-03 |
| EA009047B1 (ru) | 2007-10-26 |
| MXPA05008179A (es) | 2006-02-17 |
| MY141734A (en) | 2010-06-15 |
| AU2004208873B2 (en) | 2009-12-17 |
| HK1075898A1 (zh) | 2005-12-30 |
| DE502004007980D1 (de) | 2008-10-16 |
| ZA200505160B (en) | 2007-01-31 |
| CA2514945A1 (en) | 2004-08-19 |
| US7495096B2 (en) | 2009-02-24 |
| KR20050096165A (ko) | 2005-10-05 |
| UA81287C2 (en) | 2007-12-25 |
| EP1590351B1 (de) | 2008-09-03 |
| EA200501135A1 (ru) | 2006-02-24 |
| ES2314366T3 (es) | 2009-03-16 |
| AU2004208873A1 (en) | 2004-08-19 |
| WO2004069836A1 (de) | 2004-08-19 |
| US20060084669A1 (en) | 2006-04-20 |
| BRPI0407012A (pt) | 2006-01-10 |
| DK1590351T3 (da) | 2008-12-15 |
| DE10304141B4 (de) | 2006-03-09 |
| CN100558727C (zh) | 2009-11-11 |
| JP2006516578A (ja) | 2006-07-06 |
| AR042946A1 (es) | 2005-07-06 |
| TW200418811A (en) | 2004-10-01 |
| DE10304141A1 (de) | 2004-08-26 |
| EP1590351A1 (de) | 2005-11-02 |
| NZ541101A (en) | 2009-03-31 |
| SI1590351T1 (sl) | 2009-02-28 |
| ATE407135T1 (de) | 2008-09-15 |
| NO20053689L (no) | 2005-07-29 |
| CN1745084A (zh) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1237138A (en) | (R)-.alpha.-ETHYL-2-OXO-L-PYRROLIDINEACETAMIDE | |
| OA12917A (en) | Novel Polymorph of N-Methyl-N-(3-{3-[2-Thienylcarbonyl]-Pyrazol-[1,5-alpha]-Pyrimidin-7-YL}Pheny) Acetamide and Compositions and Methods Related thereto. | |
| CA2519490A1 (en) | Polymorphis of valsartan | |
| JPS595165A (ja) | １−アリ−ルオキシ−２，３，４，５−テトラヒドロ−３−ベンズアゼピンおよびその製法 | |
| JP2021504418A (ja) | ２−（５−メトキシイソクロマン−１−イル）−４，５−ジヒドロ−１ｈ−イミダゾールおよびその硫酸水素塩の製造方法 | |
| BR112015003520B1 (pt) | método para a produção de (r)-1,1,3-trimetil-4-aminoindano | |
| KR970011294B1 (ko) | 부스피론의 다형 결정체 형태로의 전환 방법 | |
| PT1590351E (pt) | Processos para a produção de alcalóides de quinazolina | |
| US2471047A (en) | Synthesis of 4-hydroxycoumarins | |
| US3330826A (en) | Process for the production of deriva- tives of phenothiazine and new de- rivatives | |
| US2465293A (en) | Synthesis of 4-hydroxycoumarins | |
| Barger | LII.—The action of thionyl chloride and of phosphorus pentachloride on the methylene ethers of catechol derivatives | |
| PT89380B (pt) | Processo para a preparacao de ciano-dienos e halogenopiridinas e de compostos intermedios utilizados nesse processo | |
| Jones et al. | NEW HYDROXAMIC ACIDS DERIVED FROM CYCLOPROPANE CARBOXYLIC ACID, ISOBUTYRIC ACID AND DIBENZYL-ACETIC ACID. A COMPARATIVE STUDY OF THE BECKMANN REARRANGEMENT OF THEIR DERIVATIVES. | |
| Noyes et al. | Synthesis of the α, α'-DIMETHYLADIPIC Acids, and Separation of the Racemic Acid Into Optical Isomers. | |
| JPH0710863B2 (ja) | エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用 | |
| EP0011282B1 (de) | Thienylbenzoesäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate auf Basis dieser Verbindungen | |
| ZA200404262B (en) | Process for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine). | |
| Remfry | LXIX.—Chemical constitution and hypnotic action. Acid amides and products of the condensation of malonamides and malonic esters | |
| JPS62103069A (ja) | 新規ベンズアミド、その製造方法およびこれを含む薬剤 | |
| Hope | XCII.—The condensation of ethyl sodiomalonate with ethyl citraconate and the synthesis of β-methyltricarballylic acid | |
| EP1950204A1 (en) | Amorphous form of valsartan | |
| HK1075898B (en) | Methods for producing quinazoline alkaloids | |
| Frankland et al. | XCIV.—Menthyl esters of chloroacetic, menthoxyacetic, and methylanilinoacetic acids | |
| EP0126287B1 (en) | Fluorinated compounds having analgesic and antiinflammatory activities |